{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:36:14Z","timestamp":1780515374452,"version":"3.54.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM062920"],"award-info":[{"award-number":["GM062920"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM53386"],"award-info":[{"award-number":["GM53386"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["W-31-109-Eng-38"],"award-info":[{"award-number":["W-31-109-Eng-38"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bbrc.2019.05.064","type":"journal-article","created":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T10:53:40Z","timestamp":1557658420000},"page":"974-978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I"],"prefix":"10.1016","volume":"514","author":[{"given":"Shrikant","family":"Pawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Wong-Sam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson","family":"Agniswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-7393","authenticated-orcid":false,"given":"Irene T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2019.05.064_bib1","author":"World Health Organization"},{"key":"10.1016\/j.bbrc.2019.05.064_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jinf.2012.10.026","article-title":"Implications of HIV diversity for the HIV-1 pandemic","volume":"66","author":"Hemelaar","year":"2013","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.bbrc.2019.05.064_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.bbrc.2019.05.064_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection","volume":"102","author":"Menendez-Arias","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2019.05.064_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2015.03.021","article-title":"Retroviral proteases and their roles in virion maturation","volume":"479\u2013480","author":"Konvalinka","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.bbrc.2019.05.064_bib6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nature07342","article-title":"Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease","volume":"455","author":"Tang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2019.05.064_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tips.2007.10.013","article-title":"HIV-1 protease inhibitors: effects on HIV-2 replication and resistance","volume":"29","author":"Menendez-Arias","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2019.05.064_bib8","first-page":"132","article-title":"Update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir. Med."},{"key":"10.1016\/j.bbrc.2019.05.064_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Menendez-Arias","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2019.05.064_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/v1031110","article-title":"HIV-1 protease: structural perspectives on drug resistance","volume":"1","author":"Weber","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2019.05.064_bib11","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1097\/00002030-199912030-00006","article-title":"Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy","volume":"13","author":"Nijhuis","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.bbrc.2019.05.064_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/pro.2019","article-title":"Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors","volume":"21","author":"Tie","year":"2012","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbrc.2019.05.064_bib13","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.1021\/acs.jmedchem.5b00900","article-title":"Design of HIV-1 protease inhibitors with amino-bis-tetrahydrofuran derivatives as P2-ligands to enhance backbone-binding interactions: synthesis, biological evaluation, and protein-ligand X-ray studies","volume":"58","author":"Ghosh","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2019.05.064_bib14","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/jm301519z","article-title":"Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease","volume":"56","author":"Zhang","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2019.05.064_bib15","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cmdc.201000318","article-title":"Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors","volume":"5","author":"Ghosh","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2019.05.064_bib16","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1128\/AAC.02189-12","article-title":"GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in\u00a0vitro","volume":"57","author":"Amano","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2019.05.064_bib17","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1021\/jm400768f","article-title":"Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies","volume":"56","author":"Ghosh","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2019.05.064_bib18","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1128\/AAC.04757-14","article-title":"A\u00a0novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in\u00a0vitro","volume":"59","author":"Amano","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2019.05.064_bib19","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.bmcl.2012.01.061","article-title":"Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors","volume":"22","author":"Ghosh","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.bbrc.2019.05.064_bib20","doi-asserted-by":"crossref","first-page":"12957","DOI":"10.1021\/bi960984y","article-title":"Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease","volume":"35","author":"Wondrak","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2019.05.064_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/pro.486","article-title":"Autocatalytic maturation, physical\/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance","volume":"19","author":"Sayer","year":"2010","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbrc.2019.05.064_bib22","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/pro.261","article-title":"Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease","volume":"18","author":"Louis","year":"2009","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbrc.2019.05.064_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbrc.2019.05.064_bib24","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1111\/j.1742-4658.2010.07771.x","article-title":"Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters","volume":"277","author":"Shen","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.bbrc.2019.05.064_bib25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.05.064_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.05.064_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. C Struct. Chem."},{"key":"10.1016\/j.bbrc.2019.05.064_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.05.064_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.05.064_bib30","series-title":"Pymol: an Open-Source Molecular Graphics Tool, CCP4 Newsletter on Protein Crystallography","first-page":"82","author":"DeLano","year":"2002"},{"key":"10.1016\/j.bbrc.2019.05.064_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2019.05.064_bib32","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1021\/acsomega.8b01683","article-title":"Drug resistance mutation L76V alters nonpolar interactions at the flap-core interface of HIV-1 protease","volume":"3","author":"Wong-Sam","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbrc.2019.05.064_bib33","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/0960-894X(95)00330-V","article-title":"Estimating K-I values for tight-binding inhibitors from dose-response plots","volume":"5","author":"Copeland","year":"1995","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.bbrc.2019.05.064_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jmb.2008.05.062","article-title":"Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir","volume":"381","author":"Liu","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bbrc.2019.05.064_bib35","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/bi2018317","article-title":"HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements","volume":"51","author":"Agniswamy","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2019.05.064_bib36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jmb.2008.09.031","article-title":"Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease","volume":"384","author":"Kovalevsky","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.bbrc.2019.05.064_bib37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1046\/j.1432-1327.1999.00514.x","article-title":"Structural and kinetic analysis of drug resistant mutants of HIV-1 protease","volume":"263","author":"Mahalingam","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbrc.2019.05.064_bib38","doi-asserted-by":"crossref","first-page":"58573","DOI":"10.1039\/C6RA09201B","article-title":"Drug resistance mechanisms of three mutations V32I, I47V and V82I in HIV-1 protease toward inhibitors probed by molecular dynamics simulations and binding free energy predictions","author":"Chen","year":"2016","journal-title":"RSC Adv."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19309349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19309349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T05:49:48Z","timestamp":1720158588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X19309349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0006291X19309349"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.05.064","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.05.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}